|
Post by orlon on Sept 22, 2016 11:25:41 GMT -5
I suggested last November that delisting was possible in the first quarter of 2016 just looking at the trend...I was off a bit. I still own quite few shares and like many others, I am under water. Still, I think the product is great, the potential for technosphere is great, and still believe it will succeed. Al Mann said once it should not take ten years and a billion dollars to bring a drug to market. He was correct of course, but failed to see the obstacles Afrezza faced in becoming widely used:Big pharmas such as Sanofi and Novo's profits were being threatened, the needle industry etc threatened, and the protectionists attitude of those who control the diabetic industry needed to be preserved. Throw in the short sellers including those who lend their shares to shorts then reinvests their dividends to lend more to shorts, then one has to come up with the situation we have today. The only logical step at this point is a 1/5 or maybe even a 1/10 reverse stock split to make the company's stock attractive. I suggest their are to many shares outstanding as it is, and a reservse stock split might be a good thing. The eternal optimists that post on this board believe the Pinks might not be that bad and that a reverse split would be terrible. I happen to think that thinking is wrong though many might disagree.
|
|
|
Post by orlon on Aug 30, 2016 11:21:11 GMT -5
Can anyone suggest why the stock price keeps falling like a rock?? On a side note, I saw a story on Skynews this morning about the record number of foot amputations due to type 2 diabetes in England. Comment?
|
|
|
Post by orlon on Aug 29, 2016 16:13:04 GMT -5
Form 8 after the close....another 15,000,000 shares at price no higher than .81c.
|
|
|
Post by orlon on Aug 8, 2016 14:54:28 GMT -5
Holy macaroni: Piper down to .05 and Royal Bank of Scotland to .15c!!! So my confidence in this company is only worth between .05-.15 cents? I just put a sell order in at $15.00...I have perhaps a little more time and confidence than the wiz bangers at these institutions.
|
|
|
PPS
Jul 21, 2016 12:50:51 GMT -5
alethea likes this
Post by orlon on Jul 21, 2016 12:50:51 GMT -5
Ten years in development, one billion dollar cost, three attempts at approval before finally winning approval over two years ago, sabotaged by the partnership with Sanofi for a year, a one dollar stock being shorted big time (even among those who loan their shares out to shorts for a few shekels,) for a drug that makes a difference in people's lives. And almost all I read here is hope and what ifs. I agree with those who talk up scripts...if you have a great drug SELL the drug! Pure and simple. No sale of AFREZZA then bankruptcy. I think the current management team is doing their best to get it out in the market, but resources go only so far. Further dilution would probably make the PPS less a buck...might as well go bust at that point.
|
|
|
Post by orlon on Jul 18, 2016 13:07:54 GMT -5
What wonderful news. PPS soared to $1.01 before falling back to $1.00. We need more good news and higher rating like Schwab! (Tongue in cheek statement)
|
|
|
Post by orlon on Jul 13, 2016 14:22:43 GMT -5
Peppy, doesn't cost anything to sign up. I read the article and came away with these guys learning a little and having a good time.
|
|
|
Post by orlon on May 23, 2016 11:12:54 GMT -5
Who is keeping a tight grip on the stock price, the narrow trading range, and why?
|
|
|
Post by orlon on May 20, 2016 13:32:07 GMT -5
Thank you for your rather sarcastic remarks. I know the process for delisting and how long it takes. My comment started about the narrow trading range under a dollar. Take it for what it is worth. I've heard the 'good news' before, having been a holder of this stock for many years and actually believe the company will succeed over the next year. But the challenges from the big drug companies are not going away and will only intensify putting pressure on the stock price and the company's plans. Again, thank you for sophomoric comments.
|
|
|
Post by orlon on May 19, 2016 12:42:28 GMT -5
The PPS range is tight but the threat of delisting is becoming a little more plausible. The stock has been below $1.00 for over a week and heading into a no news future.
|
|
|
Post by orlon on May 18, 2016 16:32:50 GMT -5
The PPS appears to be in a very narrow trading range recently. Volume hasn't been great aside from the private placement. Any ideas?
|
|
|
Post by orlon on Feb 26, 2016 12:57:52 GMT -5
Al Mann and Antonin Scalia have something in common...their bodies are still warm yet the conversation immediately turns to dollars and sense and politics. I guess this is who we have become as a nation.
|
|
|
Post by orlon on Feb 3, 2016 18:55:18 GMT -5
I listened to the call then read comments on both this board and the other one. So far saw a lot a negative points on both boards from calling Pffefer and the management team morons..the other board, to how GS is planning a downgrade, (I don't understand why a company so great and powerful like GS would waste time downgrading a stock under a dollar?...a bit of sarcasm here) I did not see anyone address the fact that MNKD can do little until April, when full control of AFREZZA is returned by Sanofi. I personally liked the fact that Matt addressed the individual investor questions/comments before he took questions from the rocket scientists at GS, Piper, and whoever the other guy was. I'm willing to wait, give them a chance to put their plan in action and then evaluate. I've been negative on the company myself in the past but Hakan is gone as will be the elephant in the room Sanofi in April. Maybe Matt and team have learned the Jacques Clouseau lesson in partners...trust everyone but trust no one.
|
|
|
Post by orlon on Jan 10, 2016 19:28:08 GMT -5
Up until SNY terminated the agreement, some posters on this board suggested the slow rollout was part of a secret plan. The gathering of stealth Sanofi reps gathering in a Vegas hotel, hundreds according to the source, specializing in AFREZZA, would unleash their sales skills the the medical community at any moment. Some lent their shares to be shorted then once they received their dividend from Fidelity bought more shares and shorted them...one even called it a business model. Now some are questioning whether or not the new CEO will still be there on Monday. I would like to see a change on the board that would separate the wheat from the chaff. Fact based statements backed up with source material and ideas labeled as speculation or WAGs (wild ass guesses) if they are just opinions labeled as that...speculation. Perhaps this would bring a sense of focus and normalcy back to the discussion. Just my two cents.
|
|
|
Post by orlon on Jan 9, 2016 14:36:51 GMT -5
I heard many people believe DD has quit his position after receiving news of Sanofi departure. I was asked to email Matt and have them update their website as proof that he will still be with MannKind. Since it is late Friday evening, I called, unfortunately he is not in but the receptionist instructed to read the press release regarding JPM. In the release, it states both Matt and DD will be attending the conference. In addition, Matt will be traveling next week. I will email Matt expressing everyone's concern that the website has not been updated. I suspect Matt is traveling to Paris to discuss his relocation expenses with Sanofi. Just kidding. It appears that some on this board place to much faith in Matt. It might be time for the new CEO to bring in his own management team including a new CFO.
|
|